Connor Clark & Lunn Investment Management Ltd. Raises Stake in OPKO Health, Inc. $OPK

Connor Clark & Lunn Investment Management Ltd. increased its stake in OPKO Health, Inc. (NASDAQ:OPK) by 94.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 391,664 shares of the biotechnology company’s stock after buying an additional 190,319 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in OPKO Health were worth $517,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in OPK. Vanguard Group Inc. grew its stake in OPKO Health by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 29,500,071 shares of the biotechnology company’s stock worth $48,970,000 after acquiring an additional 293,740 shares in the last quarter. AWM Investment Company Inc. boosted its holdings in shares of OPKO Health by 42.3% in the first quarter. AWM Investment Company Inc. now owns 1,850,000 shares of the biotechnology company’s stock valued at $3,071,000 after purchasing an additional 550,000 shares during the period. GSA Capital Partners LLP grew its stake in OPKO Health by 24.2% in the first quarter. GSA Capital Partners LLP now owns 1,343,701 shares of the biotechnology company’s stock worth $2,231,000 after purchasing an additional 261,495 shares in the last quarter. Washington Growth Strategies LLC increased its holdings in OPKO Health by 67,806,100.0% during the 2nd quarter. Washington Growth Strategies LLC now owns 1,356,124 shares of the biotechnology company’s stock worth $1,790,000 after purchasing an additional 1,356,122 shares during the period. Finally, Nuveen LLC purchased a new position in OPKO Health during the 1st quarter worth $2,286,000. Institutional investors own 64.63% of the company’s stock.

OPKO Health Stock Performance

OPK stock opened at $1.31 on Thursday. OPKO Health, Inc. has a one year low of $1.11 and a one year high of $2.04. The firm has a market cap of $1.01 billion, a price-to-earnings ratio of -5.24 and a beta of 1.50. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.02 and a current ratio of 3.41. The firm has a 50-day simple moving average of $1.44 and a two-hundred day simple moving average of $1.37.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $0.03 EPS for the quarter, topping the consensus estimate of ($0.02) by $0.05. OPKO Health had a negative net margin of 28.10% and a negative return on equity of 13.62%. The firm had revenue of $151.67 million during the quarter, compared to analyst estimates of $165.74 million. During the same quarter in the previous year, the business posted $0.03 EPS. OPKO Health’s revenue was down 12.6% on a year-over-year basis. On average, equities analysts forecast that OPKO Health, Inc. will post -0.25 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

OPK has been the topic of a number of recent research reports. Jefferies Financial Group reissued a “hold” rating and set a $1.60 price target (down previously from $2.00) on shares of OPKO Health in a research report on Thursday, October 30th. Wall Street Zen upgraded shares of OPKO Health from a “strong sell” rating to a “hold” rating in a report on Saturday, November 1st. Barrington Research restated an “outperform” rating and issued a $2.25 price target on shares of OPKO Health in a report on Thursday, October 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of OPKO Health in a research report on Wednesday, October 8th. Finally, Zacks Research raised shares of OPKO Health from a “strong sell” rating to a “hold” rating in a report on Thursday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $2.28.

Insider Activity at OPKO Health

In other OPKO Health news, CEO Phillip Md Et Al Frost acquired 580,000 shares of the stock in a transaction dated Wednesday, November 19th. The stock was purchased at an average price of $1.31 per share, with a total value of $759,800.00. Following the transaction, the chief executive officer directly owned 215,546,448 shares of the company’s stock, valued at $282,365,846.88. This trade represents a 0.27% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In the last ninety days, insiders acquired 1,263,300 shares of company stock worth $1,650,091. Corporate insiders own 49.69% of the company’s stock.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.